MedTrace Logo

Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19

NCT04252274 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-04-13

No results posted yet for this study

Summary

The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia

Conditions

  • Pneumonia, Pneumocystis
  • Coronavirus

Interventions

DRUG

Darunavir and Cobicistat

Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments

Sponsors & Collaborators

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2020-08-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252274 on ClinicalTrials.gov